BioNTech SE (NASDAQ:BNTX)
| 143.00 Delayed Data As of Feb 01 |  -0.36 / -0.25%Today’s Change | 117.08 Today|||52-Week Range 189.07 | -4.81% Year-to-Date |
Latest BNTX News | Press Releases
| Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down Jan 31 / Zacks.com - Paid Partner Content | FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy Jan 27 / Zacks.com - Paid Partner Content |
| The Covid sales boom is over for Pfizer Jan 31 / CNN.com | Can Pfizer (PFE) Beat Expectations This Earnings Season? Jan 26 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax Jan 30 / Zacks.com - Paid Partner Content | Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe Jan 26 / Zacks.com - Paid Partner Content |
| Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised) Jan 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 143.41 |
| Today’s open | 142.02 |
| Day’s range | 139.28 - 144.48 |
| Volume | 746,599 |
| Average volume (3 months) | 910,845 |
| Market cap | $34.8B |
Data as of 3:59pm ET, 02/01/2023
Growth & Valuation
| Earnings growth (last year) | +67,642.93% |
| Earnings growth (this year) | -11.83% |
| Earnings growth (next 5 years) | -47.70% |
| Revenue growth (last year) | +3,979.40% |
| P/E ratio | 3.3 |
| Price/Sales | 2.98 |
| Price/Book | 2.57 |
Competitors
| No competitors data available. |
Financials
| Next reporting date | March 29, 2023 |
| EPS forecast (this quarter) | $7.44 |
| Annual revenue (last year) | $22.4B |
| Annual profit (last year) | $12.2B |
| Net profit margin | 54.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
